Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of intravitreal ranibizumab + dexamethasone, oral minocycline and verteporfin photodynamic therapy for subfoveal choroidal neovascularization due to age-related macular degeneration
2006-004292-35Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab, dexamethasone, minocycline and verteporfin in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by King's College Hospital. Primary endpoints: Safety of combination intravitreal ranibizumab + dexamethasone, oral minocycline and verteporfin photodynamic therapy and Efficacy of combination intravitreal ranibizumab + dexamethasone, oral minocycline and verteporfin photodynamic therapy. Started Jan 2009; status: completed.
02
Drugs
ranibizumabdexamethasoneminocyclineverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2006-004292-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004292-35.